Serina Therapeutics announces exclusive license agreement with The Scripps Research Institute

April 3, 2013

SerinaHUNTSVILLE, Ala — Serina Therapeutics, Inc., announced today that the company has entered into a definitive exclusive license agreement with The Scripps Research Institute for “click chemistry” – a facile method of attaching molecules together in a precise and quantitative manner. The nature of the agreement and the financial terms were not disclosed.

“Click chemistry represents a major advance in how small molecules can be ‘clicked’ together,” said Mike Bentley, Ph.D. and chief scientific officer for Serina Therapeutics. “This license agreement allows us to attach small molecules to POZ polymers in a precise, quantitative and reproducible manner, and that is critical to our drug development efforts.”

Click chemistry was invented by Professor Barry Sharpless at The Scripps Research Institute. Sharpless shared the Nobel Prize in Chemistry in 2001 for his groundbreaking work in unraveling chiral catalysts.

About Serina: Serina Therapeutics is a privately held pharmaceutical company located at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala. that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled 12 approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering with pharmaceutical companies to develop high value products addressing unmet clinical needs. For more information on Serina Therapeutics, please visit their website at serinatherapeutics.com.

About The Scripps Research Institute: The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, California and Jupiter, Florida where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute’s graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top 10 of its kind in the nation. For more information, see www.scripps.edu.

Media Contact: Beth Pugh
bpugh@hudsonalpha.org
256-327-0443

About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological problems. Its mission is three-fold: sparking scientific discoveries that can impact human health and well-being; fostering biotech entrepreneurship; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus allow serendipity to yield results in medicine and agriculture. Since opening in 2008, HudsonAlpha, under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, has built a name for itself in genetics and genomics research and biotech education, and boasts 26 biotech companies on campus.

0 0 0 0 0